PDF(Sci-hub)
Abstract：
Women with endometrial or cervical cancer at risk for recurrence receive postoperative radiation therapy (RT). A patient reported outcomes (PRO) instrument to assess bowel and urinary toxicities is the Expanded Prostate Cancer Index Composite (EPIC), which has been validated in men with prostate cancer. As this instrument specifically measures bowel toxicity and the degree to which this is a problem, it was used in NRG Oncology/RTOG 1203 to compare intensity modulated RT (IMRT) to standard RT. This paper reports on the expanded validation of EPIC for use in women receiving pelvic RT.
In addition to the EPIC bowel domain, urinary toxicity (EPIC urinary domain), patient reported bowel toxicities (PRO-CTCAE) and quality of life (Functional Assessment of Cancer Therapy (FACT)) were completed before, during and after treatment. Sensitivity, reliability and concurrent validity were assessed.
Mean bowel and urinary scores among 278 women enrolled were significantly worse during treatment and differed between groups. Acceptable to good reliability for bowel and urinary domain scores were obtained at all time points with the exception of one at baseline. Correlations between function and bother scores within the bowel and urinary domains were consistently stronger than those across domains. Correlations between bowel domain scores and PRO-CTCAE during treatment were stronger than those with the FACT.
Correlations within and among the instruments indicate EPIC bowel and urinary domains are measuring conceptually discrete components of health. These EPIC domains are valid, reliable and sensitive instruments to measure PRO among women undergoing pelvic radiation.
In addition to the EPIC bowel domain, urinary toxicity (EPIC urinary domain), patient reported bowel toxicities (PRO-CTCAE) and quality of life (Functional Assessment of Cancer Therapy (FACT)) were completed before, during and after treatment. Sensitivity, reliability and concurrent validity were assessed.
Mean bowel and urinary scores among 278 women enrolled were significantly worse during treatment and differed between groups. Acceptable to good reliability for bowel and urinary domain scores were obtained at all time points with the exception of one at baseline. Correlations between function and bother scores within the bowel and urinary domains were consistently stronger than those across domains. Correlations between bowel domain scores and PRO-CTCAE during treatment were stronger than those with the FACT.
Correlations within and among the instruments indicate EPIC bowel and urinary domains are measuring conceptually discrete components of health. These EPIC domains are valid, reliable and sensitive instruments to measure PRO among women undergoing pelvic radiation.
摘要：
有复发风险的子宫内膜癌或宫颈癌妇女接受术后放射治疗（RT）。患者报告的结果（PRO）评估肠和尿毒性的工具是扩展前列腺癌指数综合指数（EPIC），这在男性前列腺癌患者中得到了验证。由于该仪器专门测量肠毒性以及这是一个问题的程度，它用于NRG肿瘤学/RTOG1203以比较强度调制RT(IMRT)与标准RT.本文报道了EPIC在接受骨盆RT的女性中使用的扩展验证。
除了EPIC肠域，尿毒性（EPIC尿结构域），患者报告肠毒性（PRO-CTCAE）和生活质量（癌症治疗功能评估（FACT））之前完成，治疗期间和之后。灵敏度,评估了信度和并发效度。
在278名入组妇女中，平均肠和尿评分在治疗期间显著恶化，且组间差异较大。在所有时间点都获得了肠和尿领域评分的可接受到良好的可靠性，基线时除外。肠和泌尿区域内的功能和打扰评分之间的相关性始终强于跨区域的相关性。治疗期间肠域评分与PRO-CTCAE之间的相关性强于FACT。
仪器内部和之间的相关性表明EPIC肠和泌尿领域在概念上测量健康的离散成分。这些EPIC域是有效的，可靠和敏感的仪器来测量PRO妇女接受盆腔辐射。
除了EPIC肠域，尿毒性（EPIC尿结构域），患者报告肠毒性（PRO-CTCAE）和生活质量（癌症治疗功能评估（FACT））之前完成，治疗期间和之后。灵敏度,评估了信度和并发效度。
在278名入组妇女中，平均肠和尿评分在治疗期间显著恶化，且组间差异较大。在所有时间点都获得了肠和尿领域评分的可接受到良好的可靠性，基线时除外。肠和泌尿区域内的功能和打扰评分之间的相关性始终强于跨区域的相关性。治疗期间肠域评分与PRO-CTCAE之间的相关性强于FACT。
仪器内部和之间的相关性表明EPIC肠和泌尿领域在概念上测量健康的离散成分。这些EPIC域是有效的，可靠和敏感的仪器来测量PRO妇女接受盆腔辐射。
